



タイトル Title	Benefits and limitations of middle bile duct segmental resection for extrahepatic cholangiocarcinoma
著者 Author(s)	Akita, Masayuki / Ajiki, Tetsuo / Ueno, Kimihiko / Tsugawa, Daisuke / Tanaka, Motofumi / Kido, Masahiro / Toyama, Hirochika / Fukumoto, Takumi
掲載誌・巻号・ページ Citation	Hepatobiliary & Pancreatic Diseases International,19(2):147-152
刊行日 Issue date	2020-04
資源タイプ Resource Type	Journal Article / 学術雑誌論文
版区分 Resource Version	author
権利 Rights	
DOI	10.1016/j.hbpd.2020.01.002
JaLCDDOI	
URL	<a href="http://www.lib.kobe-u.ac.jp/handle_kernel/90007718">http://www.lib.kobe-u.ac.jp/handle_kernel/90007718</a>

**Manuscript type:** Original Article

**Title:** Benefits and limitations of middle bile duct segmental resection for extrahepatic cholangiocarcinoma

**Running title:** middle bile duct segmental resection

**Authors:** Masayuki Akita, Tetsuo Ajiki, Kimihiko Ueno, Daisuke Tsugawa, Motofumi Tanaka, Masahiro Kido, Hirochika Toyama, Takumi Fukumoto

**Abbreviated name:** Akita M, Ajiki T, Ueno K, Tsugawa D, Tanaka M, Kido M, Toyama H, Fukumoto T

**City:** Kobe, Japan

**Author affiliations**

1 Department of Hepato-Biliary-Pancreatic Surgery,  
Kobe University Graduate School of Medicine, Kobe, Japan

**\* Corresponding author**

Tetsuo Ajiki, MD, PhD

Department of Hepato-Biliary-Pancreatic Surgery

Kobe University Graduate School of Medicine

(Tel: +81 78 382 6302; E-mail address: [ajiki@med.kobe-u.ac.jp](mailto:ajiki@med.kobe-u.ac.jp))

**CRedit authorship contribution statement:**

M.A: study design and interpretation of data; and drafting of the manuscript. K.U, D.T, M.T, M.K, H.T, and T.F: analysis of clinical data; and drafting of the manuscript. interpretation of data. T.A; drafting of the manuscript; and study supervision.

**Funding:** None

**Ethical approval:** This study was approved by the Ethics Committee of Kobe University Graduate School of Medicine. (#180367)

**Competing interest:** No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

**Additional information to the Editor, but NOT to publish:**

**Note:**

1. All author names **MUST** be in the Standard English format of **First (Given) Name, middle initial (if any), Last (Family) Name**. And the abbreviated name will be used in PubMed search.
2. Each author is required to declare his or her individual contribution to the article: all authors must have materially participated in the research and/or article preparation, so roles for all authors should be described using the relevant CRediT roles: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing - original draft, Writing - review & editing. The statement that all authors have approved the final article should be true and included in the disclosure. More details of the CRediT roles visit <https://www.casrai.org/credit.html>.
3. The *E-mail address* of Corresponding author is very important; we prefer you provide a professional *E-mail address* from your affiliation domain. **ELSEVIER will send the proof paper of the manuscript to the Corresponding Author for review and approval.**

ORIGINAL ARTICLE

**Benefits and limitations of middle bile duct segmental resection for extrahepatic  
cholangiocarcinoma**

**Running title:** middle bile duct segmental resection

**Keywords:** cholangiocarcinoma, middle bile duct resection

## **Abstract**

**Background:** Pancreatoduodenectomy (PD) is a standardized strategy for patients with middle and distal bile duct cancers. The aim of this study was to compare clinicopathological features of bile duct segmental resection (BDR) with PD in patients with extrahepatic cholangiocarcinoma.

**Methods:** Consecutive cases with extrahepatic cholangiocarcinoma who underwent BDR (n=21) or PD (n=84) with achievement of R0 or R1 resection in Kobe University Hospital between 2000 and 2016 were enrolled in the present study.

**Results:** Patients who underwent PD were significantly younger than those receiving BDR. The frequency of preoperative jaundice, biliary drainage and cholangitis was not significantly different between the two groups. The duration of surgery was longer and there was more intraoperative bleeding in the PD than in the BDR group (553 vs 421 min, and 770 vs 402 ml; both  $p < 0.01$ ). More complications ( $>$ Clavien-Dindo IIIa) were observed in the PD group (46% vs 10%,  $p < 0.01$ ). Postoperative hospital stay was also longer in that group (30 vs 19 days,  $p < 0.01$ ). Pathological assessment revealed that tumors were less advanced in the BDR group but the rate of lymph node metastasis was similar in both groups (33% in BDR and 48% in PD,  $p = 0.24$ ). The rate of R0 resection was significantly higher in the PD group (80% vs 39%,  $p < 0.01$ ). Adjuvant chemotherapy was more frequently administered to patients in the BDR group (62% vs 32%,  $p = 0.04$ ). Although 5-year overall survival rates were similar in both groups (44% for BDR and 51% for PD,  $p = 0.72$ ), in patients with T1 and 2, the BDR group tended to have poorer prognosis (44% vs 68% at 5-years,  $p = 0.09$ ).

**Conclusions:** BDR was comparable in prognosis to PD in middle bile duct cancer. Less invasiveness and lower morbidity of BDR justified this technique for selected patients in a poor general condition.

## **Introduction**

Surgical resection is the only way to achieve long-term survival in cholangiocarcinoma, and pancreatoduodenectomy or hemihepatectomy with bile duct reconstruction is the standard procedure worldwide [1-3]. However, these extensive resections are highly invasive and often result in major morbidities, such as postoperative liver failure, bile leakage or pancreatic fistula [4-6].

In a daily clinical setting, surgeons must assess the feasibility of operating on elderly patients or patients in a poor general condition. Because these patients tend to suffer from major postoperative complications, reoperation and re-admission, non-surgical treatments are often offered to them [7-11].

BDR is undertaken with curative intent for some patients with bile duct cancers confined to the middle bile duct, but there are few reports on the success of this procedure [12,13]. Some investigators suggested that prognosis for BDR was similar to PD, but BDR resulted in more R1 resection and lower numbers of harvested lymph nodes [12,13]. Some prognostic factors were identified in patients with bile duct cancer, including preoperative cholangitis, duration of surgery, lymph node metastasis, lymph node count, and adjuvant chemotherapy [14-19]. In the present study, we validated the applicability of BDR for patients with middle bile duct cancer.

## **Materials and Methods**

### **Patient selection and surgical policy**

This study was approved by the Ethics Committee of Kobe University Graduate School of Medicine. The study cohort consisted of 105 patients with bile duct cancer for whom R0 or R1 resection could be accomplished by BDR (n=21) or PD (n=84) at Kobe University Hospital between 2000 and 2016. There was no patient with in-hospital death or with conversion from BDR to PD intraoperatively. Patients suspected of having bile duct cancer were preoperatively assessed by endoscopic retrograde cholangiography, computed tomography, magnetic resonance cholangiopancreatography, and positron emission tomography. BDR was selected for patients whose tumor was found to be confined to the middle bile duct by preoperative multimodality imaging and mapping biopsy (n=10), or for patients in a poor general condition who were expected to acquire at least ductal margin with carcinoma in situ (R1 cis) resection (n=11) (Figure1). Characteristics of those patients considered to be in a poor general condition were advanced age (n=4), having severe heart disease (n=3), severe systematic disease (primary macroglobulinemia, n=1) or poor performance status (n=3). Ductal margins were routinely controlled by intraoperative rapid pathological diagnosis, and additional resection was performed for R0 when possible. Lymph node dissection was performed in the BDR group for station 12 (hepato-duodenal ligament), 8 (common hepatic artery), and 13a (infra-pancreatic area) [20].

### **Clinicopathological evaluation**

Perioperative clinicopathological data were retrospectively obtained from the electronic patient records. Preoperative presentation, serum tumor markers, surgery-associated data, pathological findings and prognosis were reviewed. Tumors were staged in accordance with the UICC/AJCC TNM classification, 7<sup>th</sup> edition [21].

## **Statistical analysis**

Continuous variables not showing a bell-shaped distribution were assessed using an unpaired t-test or Mann-Whitney U test. Categorical variables in each group were compared using the Chi-squared test or Fisher's exact test. Overall and disease free survivals were calculated using the Kaplan-Meier method. Cox regression analysis was performed using factors with  $p < 0.10$  in the univariate analysis to identify statistical significance in multivariate analysis of prognostic factors. JMP® 12 (SAS Institute Inc., Cary, NC, USA) was used for the statistical analysis.

## **Results**

### **Clinical characteristics**

As shown in Table 1, patients in the BDR group were slightly but significantly older than those in the PD group (74 vs 70 years,  $p=0.04$ ). The rates of preoperative jaundice and cholangitis were similar in the two groups (71% vs 75%,  $p=0.74$  and 62% vs 65%,  $p=0.76$ , respectively). Preoperative biliary drainage was performed in 81% of BDR group patients and 88% of the PD group ( $p=0.39$ ). No significant differences were found for serum levels of tumor markers (carcinoembryonic antigen [CEA] and carbohydrate antigen 19-9 [CA19-9]). Details of surgical procedures for PD were as follows: 19 conventional PD (23%), 10 pylorus-preserving pancreatoduodenectomy (PPPD) (12%) and 55 subtotal stomach-preserving pancreatoduodenectomy (SSPPD) (65%). Duration of surgery and blood loss were significantly less in the BDR group than in the PD group (421ml vs 553ml,  $p < 0.01$  and 402 min vs 770 min,  $p < 0.01$ , respectively). Postoperative complications (Clavien-Dindo  $> IIIa$ ) were more frequently encountered with PD (46%) than BDR (10%) ( $p < 0.01$ ). Thus, pancreatic fistula ( $n=29$ ), intraabdominal abscess ( $n=3$ ), pneumonia ( $n=2$ ), deep venous thrombosis ( $n=2$ ), bile leakage ( $n=1$ ), wound dehiscence ( $n=1$ ), and pancreatojejunum anastomotic stenosis ( $n=1$ ) were seen in the PD group, but only two intraabdominal abscesses in the BDR



group. Postoperative hospital stay was significantly shorter for patients in the BDR group (19 vs 30 days,  $p=0.02$ ). Adjuvant chemotherapy (gemcitabine or TS-1) was more commonly given to patients in the BDR group than in the PD group (62% vs 38%,  $p=0.04$ ). In BDR group, 70% of patients with a good general condition ( $n=7$ ) and 55% of those with a poor condition ( $n=6$ ) received adjuvant chemotherapy ( $p=0.46$ ).

### **Pathological findings**

There were no significant differences in tumor size, tumor differentiation status, lymphatic invasion, vascular invasion and perineural invasion between the two groups (Table 2). In BDR group, length of resected bile duct was 42mm (35-50mm: quartile range). Tumors in the BDR group were diagnosed as earlier cancer according to the T classification (T1: 14%, T2: 76% and T3: 10%), whereas those in the PD group were more advanced (T3+4: 67%). Although the frequency of lymph node metastasis was similar in the two groups, the number of retrieved lymph nodes was significantly lower in the BDR group (8 vs 13,  $p<0.01$ ). Most metastases were observed in station 12 and 13 located along the bile duct. In terms of resection margin status, in the BDR group, R0 resection rate was present in 8 cases, which was significantly lower comparing to the PD group (39% vs 80%,  $p<0.01$ ). R1 was seen in 13 patients in the BDR group (62%, one patient had 2 cancer positive margins): 4 R1cis (bile duct on the hepatic side:  $n=1$  and on the pancreatic side:  $n=3$ ) and 10 R1inv (on the hepatic side:  $n=3$ , on the pancreatic side:  $n=5$  and on the exfoliation area:  $n=2$ ). In the PD group, R1 was observed in 17 patients (39%, 2 patients had 2 cancer positive margins): R1cis (bile duct on the hepatic side:  $n=2$ ) and 17 R1inv (on the hepatic side:  $n=8$  and on the exfoliation area:  $n=9$ ).

### **Prognostic outcomes**

The median follow-up period was 26 months (range 1-160 months). There was no in-hospital mortality. Median overall survivals were 37 months in the BDR group and 62 months in the PD group. Five-year overall survival rates were similar in both groups

(44% for BDR vs 51% for PD,  $p=0.72$ ) (Figure 2A). During the follow-up period, 57 patients suffered recurrence (55%), with 5-year disease-free survival rates similar in the two groups (47% and 49%,  $p=0.99$ ) (Figure 2B). In patients with T1 and T2 cancers, there was no significant difference between PD and BDR groups (44% vs 68% at 5 years,  $p=0.09$ ) (Figure 2C). Although BDR group was composed of patients with two different clinical backgrounds, good and poor general conditions, there was no significant prognostic difference between two types of patients (45% and 41% at 5-year,  $p=0.69$ , respectively) (Figure 2D). The site of most recurrences was the liver (40% in the BDR group vs 50% in the D group), and again, there were no differences in recurrence in between the two groups (Table 3).

Cox regression analysis revealed that elevated serum CEA level and R1 resection were independent prognostic factors in this study cohort (Table 4). The nature of the surgical procedure (BDR vs PD) was not identified as a prognostic factor.

## **Discussion**

The present study has highlighted some advantages and disadvantages of BDR relative to PD. BDR was clearly a less invasive procedure than PD, with a shorter duration of surgery, less intraoperative blood loss, less postoperative complications, and a shorter hospital stay. However, disadvantages of BDR included a high rate of R1 resection and less harvested regional lymph nodes.

In general, curative surgery for distal cholangiocarcinoma requires PD. Because of the softness of the pancreatic parenchyma and narrowness of the pancreatic duct, many patients with distal bile duct cancer who underwent PD suffered from postoperative pancreatic fistula (33-48%) which prolonged the hospital stay [22-24]. However, in the present study, the lesser invasiveness of BDR might have resulted in earlier discharge and then in the administration of adjuvant chemotherapy more often. This may be one of the possible explanations of a comparable prognosis of BDR group to that of PD

group. BDR was performed especially often for patients in a poor general condition and was associated with more R1 resection, an independent prognostic factor for bile duct cancer. If these weakened patients had not undergone an operation, they might have been treated by systemic chemotherapy. Previous studies on systemic chemotherapy for patients with advanced biliary tract cancer reported a median survival time of about 8 months for patients treated with gemcitabine and about 11 months for combined gemcitabine + cisplatin [25,26]. These results are worse than seen here in the BDR group with R1 resection. Thus, patients with middle bile duct cancer who cannot tolerate PD or hepatectomy may be good candidates for BDR.

One of the disadvantages of BDR was a lower curative effect. However, in advanced extrahepatic cholangiocarcinoma, prognosis following R1cis or R0 resection is known to be similar [14,27,28], and 4 of 13 patients with R1 were able to achieve R1cis resection in the present study. In our institution, bile duct margin was assessed by intraoperative frozen section analysis. For patients with positive ductal margin, additional bile duct resection was repeatedly performed to achieve R0 status, however some cases finally resulted in positive bile duct margin. Another study reported that R1cis was an independent prognostic factor in early cholangiocarcinoma [14]. With regard to patients with T1 and 2 in the present study, BDR group had more local recurrences than PD group (31% vs 7%,  $p=0.04$ ), which maybe came from high rate of R1 resection. However, there was no significance in prognosis between BDR and PD group.

In terms of lymph node metastasis, nodal status is well-documented as a prognostic factor. Several studies reported that lymph node metastasis, positive lymph node ratio and lymph node count all had strong prognostic value [17,18,30]. A major difference in lymph node dissection between BDR and PD is that the former procedure cannot retrieve a part of the peri-pancreatic lymph nodes (station 13, 17) and all of the superior mesenteric artery lymph node (station 14). In fact, the BDR group had less lymph nodes

retrieved in this study, and one third of the patients who underwent PD had positive lymph nodes around the pancreatic head. Therefore, suspected lymph node metastasis in station 14 or 17 should not be a contraindication for BDR.

There are some limitations to this study. It is a retrospective study in a single institution, and the BDR group sample size was small. In addition, a major inclusion criterion in the BDR group was a double standard: patients in poor condition and those with cancer confined to the middle bile duct. However, the proportion of BDR to PD was totally similar to other studies (about 20%) [12,13].

In conclusion, BDR is a good option for patients with middle bile duct cancer, especially for those in a poor general condition.

## References.

1. Nagino M, Nimura Y, Nishio H, Ebata T, Igami T, Matsushita M, et al.  
Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases. *Ann Surg* 2010; 252:115–123. PMID: 20531001
2. Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, Nimura Y, et al.  
Hepatopancreatoduodenectomy for cholangiocarcinoma: a single-center review of 85 consecutive patients. *Ann Surg* 2012; 256:297–305. PMID: 22750757
3. Maeta T, Ebata T, Hayashi E, Kawahara T, Mizuno S, Matsumoto N, et al.; Nagoya Surgical Oncology Group. Pancreatoduodenectomy with portal vein resection for distal cholangiocarcinoma. *Br J Surg*. 2017;104:1549-1557. PMID: 28782798
4. Olthof PB, Wiggers JK, Groot Koerkamp B, Coelen RJ, Allen PJ, Besselink MG, et al. Postoperative Liver Failure Risk Score: Identifying Patients with Resectable Perihilar Cholangiocarcinoma Who Can Benefit from Portal Vein Embolization. *J Am Coll Surg*. 2017;225:387-394. PMID: 28687509
5. Olthof PB, Coelen RJ, Wiggers JK, Besselink MG, Busch OR, van Gulik TM. External biliary drainage following major liver resection for perihilar cholangiocarcinoma: impact on development of liver failure and biliary leakage. *HPB (Oxford)*. 2016;18:348-53. PMID: 27037204
6. Yokoyama Y, Ebata T, Igami T, Sugawara G, Mizuno T, Yamaguchi J, et al. Different Clinical Characteristics Between Distal Cholangiocarcinoma and Pancreatic Head Carcinoma With Biliary Obstruction. *Pancreas*. 2017;46:1322-1326. PMID: 28984790
7. Ahmad SA, Edwards MJ, Sutton JM, Grewal SS, Hanseman DJ, Maithel SK, et al. Factors influencing readmission after pancreaticoduodenectomy: a multi-institutional study of 1302 patients. *Ann Surg*. 2012;256:529-37. PMID: 22868373

8. Paiella S, De Pastena M, Pollini T, Zancan G, Ciprani D, De Marchi G, et al. Pancreaticoduodenectomy in patients  $\geq 75$  years of age: Are there any differences with other age ranges in oncological and surgical outcomes? Results from a tertiary referral center. *World J Gastroenterol*. 2017;23:3077-3083. PMID: 28533664
9. Casadei R, Ricci C, Lazzarini E, Taffurelli G, D'Ambra M, Mastroroberto M, et al. Pancreatic resection in patients 80 years or older: a meta-analysis and systematic review. *Pancreas*. 2014;43:1208-1218. PMID: 25333405
10. Kimura W, Miyata H, Gotoh M, Hirai I, Kenjo A, Kitagawa Y, et al. A pancreaticoduodenectomy risk model derived from 8575 cases from a national single-race population (Japanese) using a web-based data entry system: the 30-day and in-hospital mortality rates for pancreaticoduodenectomy. *Ann Surg*. 2014;259:773-780. PMID: 24253151
11. Tani M, Kawai M, Hirono S, Ina S, Miyazawa M, Nishioka R, et al. A pancreaticoduodenectomy is acceptable for periampullary tumors in the elderly, even in patients over 80 years of age. *J Hepatobiliary Pancreat Surg*. 2009;16:675-680. PMID: 19387530
12. Lee HG, Lee SH, Yoo DD, Paik KY, Heo JS, Choi SH, et al. Carcinoma of the middle bile duct: is bile duct segmental resection appropriate? *World J Gastroenterol*. 2009;15:5966-5971. PMID: 20014461
13. Kim N, Lee H, Min SK, Lee HK. Bile duct segmental resection versus pancreatoduodenectomy for middle and distal common bile duct cancer. *Ann Surg Treat Res*. 2018;94:240-246. PMID: 29732355
14. Konishi M, Iwasaki M, Ochiai A, Hasebe T, Ojima H, Yanagisawa A. Clinical impact of intraoperative histological examination of the ductal resection margin in extrahepatic cholangiocarcinoma. *Br J Surg*. 2010;97:1363-1368. PMID: 20632323

15. Yoshida T, Matsumoto T, Sasaki A, Morii Y, Aramaki M, Kitano S. Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer. *Arch Surg.* 2002;137:69-73. PMID: 11772220
16. Akita M, Ajiki T, Matsumoto T, Shinozaki K, Goto T, Asari S, et al. Preoperative Cholangitis Affects Survival Outcome in Patients with Extrahepatic Bile Duct Cancer. *J Gastrointest Surg.* 2017;21:983-989. PMID: 28290140
17. Cheng Q, Luo X, Zhang B, Jiang X, Yi B, Wu M. Distal bile duct carcinoma: prognostic factors after curative surgery. A series of 112 cases. *Ann Surg Oncol.* 2007;14:1212-1219. PMID: 17176983
18. Sasaki R, Takahashi M, Funato O, Nitta H, Murakami M, Kawamura H, et al. Prognostic significance of lymph node involvement in middle and distal bile duct cancer. *Surgery.* 2001;129:677-683. PMID: 11391365
19. Lin HP, Li SW, Liu Y, Zhou SJ. Prognostic value of lymph nodes count on survival of patients with distal cholangiocarcinomas. *World J Gastroenterol.* 2018;24:1022-1034. PMID: 29531466
20. Miyazaki M, Ohtsuka M, Miyakawa S, Nagino M, Yamamoto M, Kokudo N, et al. Classification of biliary tract cancers established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery: 3(rd) English edition. *J Hepatobiliary Pancreat Sci.* 2015;22:181-196. PMID: 25691463
21. Edge SB. *American joint committee on cancer AJCC cancer staging manual*, 7<sup>th</sup> ed. New York: Springer.
22. Petrova E, Rückert F, Zach S, Shen Y, Weitz J, Grützmann R, et al. Survival outcome and prognostic factors after pancreatoduodenectomy for distal bile duct carcinoma: a retrospective multicenter study. *Langenbecks Arch Surg.* 2017;402:831-840. PMID: 28612115
23. Andrianello S, Paiella S, Allegrini V, Ramera M, Pulvirenti A, Malleo G, et al. Pancreaticoduodenectomy for distal cholangiocarcinoma: surgical results,

- prognostic factors, and long-term follow-up. *Langenbecks Arch Surg.* 2015;400:623-628. PMID: 26134446
24. Akamatsu N, Sugawara Y, Komagome M, Shin N, Cho N, Ishida T, et al. Risk factors for postoperative pancreatic fistula after pancreaticoduodenectomy: the significance of the ratio of the main pancreatic duct to the pancreas body as a predictor of leakage. *J Hepatobiliary Pancreat Sci.* 2010;17:322-328. PMID: 20464562
25. Valle J, Wasan H, Palmer DH, Cunningham D, Anthony A, Maraveyas A, et al.; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. *N Engl J Med.* 2010;362:1273-1281. PMID: 20375404
26. Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. *Br J Cancer.* 2010;103:469-474. PMID: 20628385
27. Wakai T, Shirai Y, Moroda T, Yokoyama N, Hatakeyama K. Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma. *Cancer.* 2005;103:1210–1216. PMID: 15685618
28. Higuchi R, Ota T, Araida T, Kobayashi M, Furukawa T, Yamamoto M. Prognostic relevance of ductal margins in operative resection of bile duct cancer. *Surgery.* 2010;148:7–14. PMID: 20116818
29. Tsukahara T, Ebata T, Shimoyama Y, Yokoyama Y, Igami T, Sugawara G, et al. Residual Carcinoma In Situ at the Ductal Stump has a Negative Survival Effect: An Analysis of Early-stage Cholangiocarcinomas. *Ann Surg.* 2017;266:126-132. PMID: 27501166
30. Kawai M, Tani M, Kobayashi Y, Tsuji T, Tabuse K, Horiuchi T, et al. The ratio between metastatic and examined lymph nodes is an independent prognostic factor



for patients with resectable middle and distal bile duct carcinoma. *Am J Surg.*  
2010;199:447-452. PMID: 19596119

### **Figure Legends**

Figure 1: CT image of a representative case in BDR group. A Tumor was confined to the middle bile duct, and BDR was selected because of advanced age (83 years old). Tumor extension was confirmed by the preoperative mapping biopsy, and BDR (left and right hepatic bile duct resection) was performed.

Figure 2: Prognostic analyses. (A, B) Five-year overall and disease-free survival rates, these prognoses were similar between BDR and PD groups (44% vs 51%,  $p=0.72$ , and 47% vs 49%,  $p=0.99$ , respectively). (C) Prognostic sub-analysis in patients with T1 and T2 cancers; there was no significant difference between two groups ( $p=0.09$ ). (D) Prognostic sub-analysis in patients with good and poor general conditions revealed no different survival rates ( $p=0.69$ ).

Table 1: Clinical features between bile duct segmental resection group and pancreatoduodenectomy group.

	BDR n=21	PD n=84	p value
Age (years)	74 [70-76]	70 [64-75]	0.04
Male/Female	14 (67%)/7 (33%)	61 (73%)/23 (27%)	0.59
Jaundice	15 (71%)	63 (75%)	0.74
Biliary drainage	17 (81%)	74 (88%)	0.39
Preoperative cholangitis	13 (62%)	55 (65%)	0.76
Total Bilirubin	0.8 [0.6-1.4]	0.9 [0.6-1.4]	0.84
CEA	2.6 [2.0-3.3]	2.7 [1.7-3.3]	0.68
CA19-9	63 [20-188]	32 [15-113]	0.25
Operation			
Conventional PD		19 (23%)	
PPPD		10 (12%)	
SSPPD		55 (65%)	
BDR	21 (100%)		
Operation time (min)	421 [367-481]	553 [408-617]	<0.01
Blood loss (ml)	402 [222-590]	770 [473-1253]	<0.01
Complication CD>IIIa	2 (10%)	39 (46%)	<0.01
Hospital stay (days)	19 [13-30]	30 [18-44]	0.02
Adjuvant chemotherapy	13 (62%)	32 (38%)	0.04

Continuous variables were shown as a median [quartile]. CEA; carcinoembryonic antigen, CA19-9; carbohydrate antigen 19-9, PD; pancreatoduodenectomy, PPPD; pylorus-preserving pancreatoduodenectomy, SSPPD; subtotal stomach preserving pancreatoduodenectomy, BDR; bile duct segmental resection, CD; Clavien-Dindo.

Table 2: Pathological findings

	BDR n=21	PD n=84	p value
Size (mm)	25 [20-30]	25 [20-35]	0.64
Differentiation			0.39
Well	11 (52%)	33 (39%)	
Moderate	7 (33%)	42 (50%)	
Poor	3 (15%)	9 (11%)	
Lymphatic invasion	11 (52%)	53 (63%)	0.37
Vascular invasion	14 (67%)	50 (60%)	0.55
Perineural invasion	19 (90%)	68 (81%)	0.30
Pancreas invasion	NA	54 (64%)	
Duodenum invasion	NA	23 (27%)	
UICC T			<0.01
1	3 (14%)	7 (8%)	
2	16 (76%)	21 (25%)	
3	2 (10%)	55 (65%)	
4	0	1 (2%)	
Harvested LN number	8 [3-12]	13 [9-21]	<0.01
LN positive	7 (33%)	40 (48%)	0.24
#17	NA	6 (7%)	
#12,13	7 (33%)	38 (45%)	
#8	1 (5%)	1 (1%)	
#14	0	2 (3%)	
Residual cancer			<0.01
R0	8 (38%)	67 (80%)	
R1*	13 (62%)	17 (20%)	
(EM, HM, PM)	(2, 4, 8)	(9, 10, NA)	

Continuous variables were shown as a median [quartile]. LN; lymph node, EM; exfoliation margin, HM; hepatic side margin, PM; pancreatic side margin

\*: Three patients had 2 cancer positive margins

Table 3: Primary recurrent sites

	BDR n=21	PD n=84	p value
Recurrence	15	42	
Local	5 (33%)	14 (33%)	1.00
Liver	6 (40%)	21 (50%)	0.51
Lymph node	3 (20%)	12 (29%)	0.52
Peritoneum	2 (13%)	5 (12%)	0.89

Table 4: Prognostic factors assessed in uni- and multivariate analyses


Variables	N	Univariate		Multivariate	
		p	Odds ratio (95% CI)	P	Hazard ratio (95% CI)
Gender M/F	75/30	0.83	1.04 (0.58-2.12)		
Age >75/≤75	27/78	0.81	0.91 (0.41-1.83)		
Jaundice +/-	78/27	0.14	1.69 (0.85-3.75)		
Biliary drainage +/-	91/14	0.82	1.11 (0.50-2.92)		
Preoperative Cholangitis +/-	68/37	0.21	1.49 (0.80-2.88)		
CEA >5.0/≤5.0	10/95	0.07	2.44 (0.92-5.39)	0.04	2.98 (1.07-7.24)
CA19-9 >37/≤37	50/55	0.45	1.26 (0.69-2.28)		
Procedure BDR/PD	21/84	0.30	1.41 (0.73-2.61)		
Operation time >600/≤600	85/20	0.47	0.79 (0.42-1.56)		
Blood loss >1000/≤1000 ml	84/21	0.19	0.65 (0.35-1.25)		
Complication ≥CD IIIa +/-	41/64	0.67	0.87 (0.45-1.61)		
Hospital stay >30/≤30	50/55	0.94	0.98 (0.54-1.76)		
Tumor size >25/≤25	53/52	0.11	1.64 (0.91-3.01)		
Differentiation Well+mod/Poor	93/12	0.24	1.92 (0.70-7.95)		

UICC T 1+2/3+4	49/56	0.67	1.13 (0.63-2.06)		
Lymph node metastasis +/-	47/58	0.09	1.69 (0.92-3.10)	0.32	1.37 (0.73-2.56)
Lymphatic invasion +/-	64/41	0.24	1.46 (0.79-2.83)		
Vascular invasion +/-	65/40	0.22	1.46 (0.80-2.79)		
Perineural invasion +/-	86/19	0.03	2.69 (1.08-8.97)	0.22	1.86 (0.71-6.37)
Residual cancer R1/R0	30/75	<0.01	2.28 (1.25-4.10)	<0.01	2.42 (1.26-4.64)
Adjuvant chemo +/-	45/60	0.64	1.15 (0.64-2.08)		


CEA; carcinoembryonic antigen, CA19-9; carbohydrate antigen 19-9, PD; pancreatoduodenectomy, BDR; bile duct segmental resection, CD; Clavien-Dindo.









No. at risk	0yr	1yr	3yrs	5yrs
BDR	21	20	11	5
PD	84	62	30	14



No. at risk	0yr	1yr	3yrs	5yrs
BDR	21	18	9	5
PD	84	51	26	11



No. at risk	0yr	1yr	3yrs	5yrs
BDR	19	18	10	5
PD	28	20	11	5



No. at risk	0yr	1yr	3yrs	5yrs
Good	10	10	6	3
Poor	11	10	7	2